Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.

Details

Ressource 1Download: 16622435_BIB_E78C55F4BD38.pdf (149.81 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_E78C55F4BD38
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Journal
British journal of cancer
Author(s)
Betticher D.C., Hsu Schmitz S.F., Tötsch M., Hansen E., Joss C., von Briel C., Schmid R.A., Pless M., Habicht J., Roth A.D., Spiliopoulos A., Stahel R., Weder W., Stupp R., Egli F., Furrer M., Honegger H., Wernli M., Cerny T., Ris H.B.
ISSN
0007-0920
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
94
Number
8
Pages
1099-106
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Abstract
The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 mg m-2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.
Keywords
Adult, Aged, Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant, Cisplatin, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Recurrence, Risk Assessment, Survival Rate, Taxoids, Time Factors, Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
29/01/2008 13:00
Last modification date
20/08/2019 16:10
Usage data